JPRN-UMIN000008565已完成2 期
Multicenter Phase II Clinical Study of the research on optimal assessments and treatment strategy of nilotinib in newly diagnosed chronic myelogenous leukemia patients in the chronic phase (CML-CP) based on early achievement of complete molecular response (CMR); N-road - N-road trial
Cooperative study between Jikei University Kashiwa Hospital and Shimousa Hematology Study Group0 个研究点目标入组 50 人开始时间: 2012年8月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Previously treated by tyrosine kinase inhibitors other than imatinib 2.Previously received imatinib for more than 2 weeks 3.Previous treatment experience with IFN-alpha 4.Received oral anticancer drugs such as hydroxyurea for more than 3 months. 5.Confirmed to have the T315I point mutation of BCR-ABL 6.History of hematopoietic stem cell transplantation 7.Patients with cardiovascular dysfunction 8.Other uncontrolled complications. 9.Pregnant women or those with suspected pregnancy. Nursing women and those who plan to become pregnant during the study period.
研究者
相似试验
未知
2 期
A phase 2 multicenter clinical study evaluating the safety and efficacy of Nilotinib in patients with Imatinib- resistant/intolerant CML in chronic phaseChronic myelogenous leukemiaJPRN-UMIN000001927Tokyo STI Study Group50
进行中（未招募）
不适用
A multicenter phase II clinical trial assessing the efficacy of the combination of lapatinib and capecitabine in patients with non pretreated brain metastasis from HER2 positive breast cancer. - LANDSCAPEEUCTR2008-001084-10-FRFNCLCC
招募中
不适用
The Clinical Trial of Low Dose Irradiation for Alzheimer's DiseaseDiseases of the nervous systemKCT0007550Kyung Hee University Hospital at Gangdong60
招募中
2 期
A multicenter phase II study to evaluate the efficacy and safety of fixed-duration sequential treatment combined with novel agents and autologous stem cell transplantation for newly diagnosed elderly multiple myeloma. -JSCT EMM21Multiple myelomaJPRN-jRCTs071210084Kikushige Yoshikane75
进行中（未招募）
1 期
A clinical trial to evaluate the efficacy and safety ofpembrolizumab and gemcitabine in patients with HER2-negative Advanced Breast Cancer. PANGEA-Breast”Patients with HER2-negative advanced breast cancer.MedDRA version: 19.0Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2016-001779-54-ESGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)36